Osteoprotegerin and DNA repair gene (OGG1 and XRCC1) in females with breast cancer
Abstract
Abstract:
Breast cancer is one of the most widespread cancers around the world and it is the second main reason for death after lung cancer among women. Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor super family. Numerous preclinical and clinical studies have been conducted to assess the participation of OPG in tumorigenesis and cancer development. Mammalian cells are constantly exposed to genotoxic agents from both endogenous and exogenous sources. Genetic variability in DNA repair contributes to deficient repair and breast cancer risk. Using samples collected in an ongoing, clinic-based, case-control study 68 cases (34 females’ pre-diagnosis with breast cancer and 34 females who received one and/or tow dose of chemotherapy) compared to 34 females as control. In addition to vitamins and oxidative stress parameters we tested whether breast cancer risk is associated with four amino acid substitution variants in tow DNA repair genes, including OGG1 Ser326 Cys and XRCC1 Arg399Gln in base excision repair. The frequency distribution of OGG1 in the Pre-diagnosis group allele G/C (heterozygous) genotype, those with an allele C/C (homozygous) genotype with a 43% risk factor were more likely to have an illness with ratio was 72% allele C and 28% allele G, whereas for controls, the ratio was 60% allele C and 40% allele G. The odds ratios of specific chemotherapy Breast cancer subpopulations compared with control for CC subjects was 0.26(95% CI,0.05–1.31), CG subjects were 0.02(95% CI,0.00–0.28) and GG subjects was 81.0 (95% CI,12.8–512.4). These results make use of the pathways and mechanisms that have been found and offer practical treatment options for breast cancer. Future studies should clarify OPG's function and usefulness as a biomarker and target for treatment. OGG1 germ line mutations and the risk of breast cancer were found to be significantly correlated. These results show that OGG1 might be a promising candidate for improved breast cancer detection, management, and prevention.
Keywords
Full Text:
PDFReferences
References:
Ali, K., Mahjabeen, I., Sabir, M., Mehmood, H., & Kayani, M. A. (2015). OGG1 Mutations and Risk of Female Breast Cancer: Meta-Analysis and Experimental Data. Disease Markers, 2015, 1–16. https://doi.org/10.1155/2015/690878
Barili, V., Ambrosini, E., Bortesi, B., Minari, R., De Sensi, E., Cannizzaro, I. R., Taiani, A., Michiara, M., Sikokis, A., Boggiani, D., Tommasi, C., Serra, O., Bonatti, F., Adorni, A., Luberto, A., Caggiati, P., Martorana, D., Uliana, V., Percesepe, A., … Pellegrino, B. (2024). Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing. Genes, 15(2), 219. https://doi.org/10.3390/genes15020219
Berg, H. (2012). Restriction Fragment Length Polymorphism Analysis of PCR-Amplified Fragments (PCR-RFLP) and Gel Electrophoresis - Valuable Tool for Genotyping and Genetic Fingerprinting. In Gel Electrophoresis - Principles and Basics. InTech. https://doi.org/10.5772/37724
Cai, Q., Shu, X.-O., Wen, W., Courtney, R., Dai, Q., Gao, Y.-T., & Zheng, W. (2006). Functional Ser326Cys Polymorphism in the hOGG1 Gene Is Not Associated with Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 15(2), 403–404. https://doi.org/10.1158/1055-9965.EPI-05-0868
Clarke, T. L., & Mostoslavsky, R. (2022). DNA repair as a shared hallmark in cancer and ageing. Molecular Oncology, 16(18), 3352–3379. https://doi.org/10.1002/1878-0261.13285
Datkhile, K., Gudur, R., Bhosale, S., Durgawale, P., Jagdale, N., More, A., Gudur, A., & Patil, S. (2023). Impact of Interaction between Single Nucleotide Polymorphism of XRCC1, XRCC2, XRCC3 with Tumor Suppressor Tp53 Gene Increases Risk of Breast Cancer: A Hospital Based Case-Control Study. Asian Pacific Journal of Cancer Prevention, 24(9), 3065–3075. https://doi.org/10.31557/APJCP.2023.24.9.3065
Dubey, A., & Sharma, B. (2025). Targeting Oxidative Stress Biomarkers in Breast Cancer Development and the Potential Protective Effect of Phytochemicals. Drugs and Drug Candidates, 4(2), 23. https://doi.org/10.3390/ddc4020023
Elfar, G. A., Ebrahim, M. A., Elsherbiny, N. M., & Eissa, L. A. (2017). Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 25(4), 641–650. https://doi.org/10.3727/096504016X14768398678750
Falagan-Lotsch, P., Rodrigues, M. S., Esteves, V., Vieira, R., Amendola, L. C., Pagnoncelli, D., Paixão, J. C., & Gallo, C. V. D. M. (2009). XRCC1 gene polymorphisms in a population sample and in women with a family history of breast cancer from Rio de Janeiro (Brazil). Genetics and Molecular Biology, 32(2), 255–259. https://doi.org/10.1590/S1415-47572009000200008
Filip, C. I., Cătană, A., Pîrlog, L.-M., Pătrășcanu, A.-A., Militaru, M. S., Iordănescu, I., & Dindelegan, G. C. (2025). Associations Between DNA Repair Gene Polymorphisms and Breast Cancer Histopathological Subtypes: A Preliminary Study. Journal of Clinical Medicine, 14(11), 3764. https://doi.org/10.3390/jcm14113764
Geerts, D., Chopra, C., & Connelly, L. (2020). Osteoprotegerin: Relationship to Breast Cancer Risk and Prognosis. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.00462
Hindi, N. N., Elsakrmy, N., & Ramotar, D. (2021). The base excision repair process: comparison between higher and lower eukaryotes. Cellular and Molecular Life Sciences, 78(24), 7943–7965. https://doi.org/10.1007/s00018-021-03990-9
Huang, R., & Zhou, P.-K. (2021). DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy, 6(1), 254. https://doi.org/10.1038/s41392-021-00648-7
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019). RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. Journal of Experimental & Clinical Cancer Research, 38(1), 12. https://doi.org/10.1186/s13046-018-1001-2
Liu, W., Xu, C., Zhao, H., Xia, P., Song, R., Gu, J., Liu, X., Bian, J., Yuan, Y., & Liu, Z. (2015). Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway. PLOS ONE, 10(11), e0142519. https://doi.org/10.1371/journal.pone.0142519
Momivand, M., Razaghi, M., Mohammadi, F., Hoseinzadeh, E., & Najafi-Vosough, R. (2024). The status of serum 25(OH)D levels is related to breast cancer. Cancer Treatment and Research Communications, 42, 100870. https://doi.org/10.1016/j.ctarc.2025.100870
Nechuta, S., Lu, W., Chen, Z., Zheng, Y., Gu, K., Cai, H., Zheng, W., & Shu, X. O. (2011). Vitamin Supplement Use During Breast Cancer Treatment and Survival: A Prospective Cohort Study. Cancer Epidemiology, Biomarkers & Prevention, 20(2), 262–271. https://doi.org/10.1158/1055-9965.EPI-10-1072
Nsaif, N. S. A. H. R. A. R. A. S. (2019). Relationship between Breast cancer and Vitamin A and Family history of Iraqi women population. Research Journal of Biotechnology, 14(Special Issue I).
Radhi, J. H., El-Hagrasy, A. M. A., Almosawi, S. H., Alhashel, A., & Butler, A. E. (2025). The Role of Osteoprotegerin in Breast Cancer: Genetic Variations, Tumorigenic Pathways, and Therapeutic Potential. Cancers, 17(3), 337. https://doi.org/10.3390/cancers17030337
Rossner, P., Terry, M. B., Gammon, M. D., Zhang, F. F., Teitelbaum, S. L., Eng, S. M., Sagiv, S. K., Gaudet, M. M., Neugut, A. I., & Santella, R. M. (2006). OGG1 Polymorphisms and Breast Cancer Risk. Cancer Epidemiology, Biomarkers & Prevention, 15(4), 811–815. https://doi.org/10.1158/1055-9965.EPI-05-0659
Ruan, J., Zhou, H., E, Z., Chu, Y., Zhang, S., Liao, J., Zhou, W., & Chen, B. (2025). Association Between Seven Selected Genetic Polymorphisms in DNA Repair-Related Genes and Breast Cancer Risk: Evidence from a Comprehensive Meta-analysis Including 96 Studies. Biochemical Genetics. https://doi.org/10.1007/s10528-025-11181-5
Salih, H. H., Abd, S. Y., Al-Kaseer, E., & Al-Diwan, J. (2025). Cancer in Iraq, general view of annual report 2022. Journal of Contemporary Medical Sciences, 10(6). https://doi.org/10.22317/jcms.v10i6.1676
Sarink, D., Schock, H., Johnson, T., Overvad, K., Holm, M., Tjønneland, A., Boutron-Ruault, M.-C., His, M., Kvaskoff, M., Boeing, H., Lagiou, P., Papatesta, E.-M., Trichopoulou, A., Palli, D., Pala, V., Mattiello, A., Tumino, R., Sacerdote, C., Bueno-de-Mesquita, H. B., … Fortner, R. T. (2017). Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort. Cancer Prevention Research, 10(9), 525–534. https://doi.org/10.1158/1940-6207.CAPR-17-0125
Sharma, R., Lewis, S., & Wlodarski, M. W. (2020). DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns. Frontiers in Pediatrics, 8. https://doi.org/10.3389/fped.2020.570084
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68(1), 7–30. https://doi.org/10.3322/caac.21442
Tas, F., Hansel, H., Belce, A., Ilvan, S., Argon, A., Camlica, H., & Topuz, E. (2005). Oxidative Stress in Breast Cancer. Medical Oncology, 22(1), 011–016. https://doi.org/10.1385/MO:22:1:011
Wang, W., Wang, M., Chen, Y., Zhang, Z., Wang, S., Xu, M., Wang, B., Zhao, Q., & Zhang, Z. (2012). The hOGG1 Ser326Cys polymorphism contributes to cancer susceptibility: evidence from 83 case-control studies. Mutagenesis, 27(3), 329–336. https://doi.org/10.1093/mutage/ger083
Wang, Y., Liu, Y., Huang, Z., Chen, X., & Zhang, B. (2022). The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discovery, 8(1), 252. https://doi.org/10.1038/s41420-022-01042-0
Wu, X., Li, F., Dang, L., Liang, C., Lu, A., & Zhang, G. (2020). RANKL/RANK System-Based Mechanism for Breast Cancer Bone Metastasis and Related Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 8. https://doi.org/10.3389/fcell.2020.00076
Yuan, W., Xu, L., Feng, Y., Yang, Y., Chen, W., Wang, J., Pang, D., & Li, D. (2010). The hOGG1 Ser326Cys polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment, 122(3), 835–842. https://doi.org/10.1007/s10549-009-0722-5
Zoubi, M. S. Al. (2015). X-ray repair cross-complementing protein 1 and 3 polymorphisms and susceptibility of breast cancer in a Jordanian population. Saudi Medical Journal, 36(10), 1163–1167. https://doi.org/10.15537/smj.2015.10.12659
Refbacks
- There are currently no refbacks.